Skip to content

Inspection Record

Genzyme Ireland Limited — FDA 483 Findings

US FDAInspected 2025-01-17Published 2026-11-12 4 findingsAseptic processing and sterility assuranceOther quality systemEquipment and facility

View the regulator's official source The source document is always the basis for judgement.

Findings

1Aseptic processing and sterility assurance

Procedures, process and testing designed to prevent microbial contamination of the drug product purporting to be sterile are not established.

2Other quality system

The “systems in support of ®®drug product manufacture are not adequately maintained.

3Equipment and facility

Equipment used in the QC Microbiological Lab is not adequately maintained.

4Other quality system

A standard operating procedure was not followed.

A record as of the US FDA document published on 2026-11-12. Check the agency's announcements for any later corrective action, and rely on the original text. Translation and classification are machine-made.

Other records for this company

Genzyme Ireland Limited findings history — including this company's other documentsAll US FDA findings US FDA documents, 2026 Go to Findings search
Weekly Newsletter

Get new findings like these every Monday

Every Monday we email the week's new findings and actions from the FDA, EMA, Health Canada and MFDS. Each one links to its record on our site, where you'll find the regulator's original document. We'll also let you know when the site gains new features. Unsubscribe any time with one click.

See recent findings first

Sent every Monday · a confirmation email follows when you subscribe · unsubscribe from the footer of any email.